Cytek Biosciences (NASDAQ:CTKB) Stock Rating Raised to “Buy” at Wall Street Zen

Cytek Biosciences (NASDAQ:CTKB – Get Free Report) was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report issued on Saturday, Wall Street Zen reports.

A number of other research analysts have also recently commented on the company. Stephens restated an “overweight” rating and issued a $6.00 target price on shares of Cytek Biosciences in a research note on Friday, October 23rd. Morgan Stanley set a $5.00 price target on Cytek Biosciences in a report on Friday, August 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cytek Biosciences in a report on Monday, September 21st. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $5.88.

View Our Latest Report on CTKB

Cytek Biosciences Trading Up 8.0%

CTKB opened at $5.83 on Friday. The company’s fifty day moving average price is $5.39 and its two-hundred day moving average price is $4.67. The company has a market cap of $757.78 million, a price-to-earnings ratio of -9.25 and a beta of 1.15. Cytek Biosciences has a 1-year low of $3.31 and a 1-year high of $6.34.

Cytek Biosciences (NASDAQ:CTKB – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.02. The company had revenue of $53.23 million for the quarter, compared to analysts’ expectations of $53.05 million. Cytek Biosciences had a negative return on equity of 12.40% and a negative net margin of 38.98%. As a group, equities analysts forecast that Cytek Biosciences will post -0.36 earnings per share for the current fiscal year.

Institutional Trading of Cytek Biosciences

Institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. purchased a new position in shares of Cytek Biosciences during the second quarter worth about $42,433,000. Hhlr Advisors LTD. acquired a new stake in shares of Cytek Biosciences during the 2nd quarter worth about $29,491,000. Russell Investments Group Ltd. boosted its holdings in shares of Cytek Biosciences by 60.7% during the third quarter. Russell Investments Group Ltd. now owns 2,428,747 shares of the company’s stock valued at $14,475,000 after acquiring an additional 917,432 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Cytek Biosciences by 0.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,663,329 shares of the company’s stock valued at $11,638,000 after buying an additional 16,438 shares in the last quarter. Finally, Bank of America Corp DE acquired a new position in shares of Cytek Biosciences during the second quarter worth approximately $5,827,000. 69.46% of the stock is currently owned by institutional investors.

Cytek Biosciences Company Profile

(Get Free Report)

Cytek Biosciences, Inc develops and commercializes cell analysis solutions for biomedical research, clinical research and biopharmaceutical applications. The company focuses on spectral flow cytometry, a technology that enables researchers to analyze multiple characteristics of individual cells and identify complex cell populations.

Its product portfolio includes the Aurora and Northern Lights spectral flow cytometers, compact and specialized instruments, cell sorters, software and a range of fluorescent reagents.

Further Reading

Analyst Recommendations for Cytek Biosciences (NASDAQ:CTKB)

Receive News & Ratings for Cytek Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytek Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.